Company Overview and News
LGI Homes, Inc. (LGIH - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for LGIH broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
Rifles are the investment weapons of choice right now on Wall Street. I’m referring to strategies I call “rifle-shots,” because these investors scan the investment horizon through their rifle scopes and only pull the trigger when they spot a particularly attractive stock.
Welcome to the anniversary of the Brunch, Craft Beer, and Investing Portfolio reviews. If this is your first time, the following paragraph is just for you.
LRCX NEWR FB BZUN TWX CACI SLP KLAC NWL AMAT ACN DXC.WI DXC ROL CACU LGIH CARA MA TWC CTSH V PLD MKSI MSFT TTD
THE WOODLANDS, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nasdaq:LGIH) today announced 637 homes closed in June 2018, up from 623 home closings in June 2017, representing year-over-year growth of 2.2%. In addition, the Company announced quarterly home closings of 1,815 for the second quarter of 2018 compared to 1,511 home closings in the second quarter of 2017, a 20.1% increase year-over-year.
MOLALLA, Ore., July 02, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nasdaq:LGIH) today announces the opening of its first community in the state of Oregon, Bear Creek. This new 128-lot development, located southeast of Portland, exemplifies the national homebuilder’s plans for expansion in 2018 and beyond.
THE WOODLANDS, Texas, June 28, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ:LGIH) (“LGI Homes” or the “Company”) today announced that it has priced its previously announced offering of $300,000,000 aggregate principal amount of unsecured Senior Notes due 2026 (the “Notes”) to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.
THE WOODLANDS, Texas, June 21, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ:LGIH) (“LGI Homes” or the “Company”) today announced that it has commenced a private offering of $400,000,000 aggregate principal amount of unsecured Senior Notes due 2026 (the “Notes”) to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.
RIO VISTA, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nadaq:LGIH) has expanded operations into the state of California with the opening of Liberty, a new community in the East Bay area, centrally located between Sacramento and San Francisco.
That means when the economic numbers are on the rise, the U.S. consumer is also on the rise. The Federal Reserve just raised interest rates for the second time this year and it says it will likely raise it two more times in 2018. And instead of rocking the market, the market took it as a positive sign that the 10-year economic doldrums may be at an end. I’ll take it one step at a time.
LW PLNT MMYT PRMW EL LGIH NUS HEAR SAM CENT
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET